SCN1A and benign familial infantile epilepsy: She may accrue future revenue on the pending patents: WO/2006/133508: Patent for SCN1A testing held by Bionomics Inc and licenced to various diagnostic companies, WO/2013/059884: Patent for a molecular diagnostic/therapeutic target for benign familial infantile epilepsy (BFIE) [PRRT2] with royalties paid, WO2009/086591: May accrue future revenue on pending patent: Diagnostic And Therapeutic Methods For EFMR (Epilepsy And Mental Retardation Limited To Females).